Jasbir Seehra's most recent trade in Keros Therapeutics Inc was a trade of 217,000 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 24, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 217,000 | 217,000 | - | - | Employee Stock Option (Right to Buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2026 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 16.17 per share. | 19 Feb 2026 | 7,015 | 385,708 | - | 16.2 | 113,433 | Common Stock |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 62,500 | 62,500 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2025 | 90,500 | 392,723 | - | 0 | Common Stock | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 04 Apr 2025 | 49,367 | 302,223 | - | 0.3 | 14,810 | Common Stock |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2025 | 49,367 | 252,444 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2023 | 4,000 | 45,087 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.48 per share. | 08 Apr 2023 | 4,000 | 252,856 | - | 0.5 | 1,920 | Common Stock |
| Keros Therapeutics Inc | Jasbir Seehra | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Eloxx Pharmaceuticals Inc | Jasbir Seehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 20,000 | 20,000 | - | - | Stock Options (Right to Buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 09 Jun 2022 | 5,000 | 248,856 | - | 0.3 | 1,500 | Common Stock |
| Keros Therapeutics Inc | Jasbir Seehra | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2022 | 5,000 | 8,822 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Jasbir Seehra | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 165,000 | 165,000 | - | - | Employee Stock Option (right to buy) | |
| Eloxx Pharmaceuticals Inc | Jasbir Seehra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |